JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

被引：10
|
作者：
Sivanandhan, Dhanalakshmi [1 ]
Rajagopal, Sridharan [1 ]
Nair, Sreekala [2 ]
Basavaprabhu, B. [2 ]
Dhkar, Reshma [2 ]
Viswakarma, Santosh [2 ]
Siddiqui, Amir [2 ]
Zainuddin, Mohd [2 ]
Rudresh, G. [2 ]
Daram, Prashanthi [2 ]
Mohire, Sunil [2 ]
Krishnakumar, V [2 ]
机构：
[1] Jubilant Therapeut Ltd, Yardley, PA USA
[2] Jubilant Biosys Ltd, Bangalore, Karnataka, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1756
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
    Sethy, Bidyadhar
    Upadhyay, Richa
    Narwanti, Iin
    Yu, Zih-Yao
    Lee, Sung-Bau
    Liou, Jing-Ping
    APOPTOSIS, 2024, 29 (11-12) : 2047 - 2073
  • [32] Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer
    Li, Zhong-Hua
    Zhang, Xiao-Bing
    Han, Xi-Qian
    Feng, Cong-Ran
    Wang, Feng-Shan
    Wang, Peng George
    Shen, Jie
    Shi, Yi-Kang
    ONCOLOGY REPORTS, 2013, 30 (01) : 499 - 505
  • [33] Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer
    Jia, Geng
    Qi, Kangjing
    Hou, Baogeng
    Yue, Kairui
    Xu, Tongqiang
    Jiang, Yuqi
    Li, Xiaoyang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 260
  • [34] Design, synthesis, and evaluation of a novel TRAIL-activated HDAC6 inhibitor for the treatment of pulmonary fibrosis
    Gao, Ying
    Wang, Pengfeng
    Hu, Zan
    Cui, Hao
    Chen, Xuxi
    Wang, Liqun
    Zhao, Manyu
    Qian, Rui
    Zhang, Ling
    Ye, Tinghong
    Zhu, Yong
    Yao, Yuqin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 113
  • [35] Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies
    Huang, Ziqian
    Li, Ling
    Cheng, Binbin
    Li, Deping
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 178
  • [36] Preclinical evaluation of the compound 4SC-202, a combined LSD1-and HDAC inhibitor, for the treatment of cutaneous T cell lymphoma
    Wobser, M.
    Weber, A.
    Glunz, A.
    Kohlhof, H.
    Goebeler, M.
    Schrama, D.
    Houben, R.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E41 - E41
  • [37] Discovery of a novel CDK4/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma
    Niu, Zizhou
    Shi, Zhichao
    Wu, Guoxiang
    Liu, Yanping
    Xie, Weibin
    Liu, Fakai
    Fan, Tingting
    Shu, Kaifei
    Huang, Qiuhua
    Dai, Mengmeng
    Zhi, Cailian
    Qiu, Cheng
    Li, Yilin
    Wu, Lihong
    Liu, Funian
    Zhang, Yijie
    Wu, Tingbiao
    Chen, Yan
    Liu, Zijian
    Hao, Yue
    Jiang, Yuyang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [38] Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer
    Zhang, Jin
    Chen, Xiya
    Chen, Gang
    Wang, Hailing
    Jia, Lin
    Hao, Yue
    Yao, Dahong
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 251
  • [39] Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation
    Geng, Hefeng
    Zheng, Fangyuan
    Sun, Wentao
    Huang, Shuoqi
    Wang, Zhiya
    Yang, Kaisi
    Wang, Chengkang
    Tian, Caizhi
    Xu, Chang
    Zhai, Guanchao
    Zhao, Mingyi
    Hou, Shanbo
    Song, Aigang
    Zhang, Yingshi
    Zhao, Qingchun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [40] Examination of therapeutic potential of epigenetic modulation by dual HDAC-LSD1 inhibition in murine models of triple negative breast cancer (TNBC)
    Messerli, Shanta M.
    Hoffman, Mariah M.
    Zylla, Jessica S.
    Gnimpieba, Etienne
    Miskimins, Keith W.
    CANCER RESEARCH, 2020, 80 (16)
12345